Article
Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreatic cancer.
Pathology oncology research : POR - 1 Jan 2024
Molnár Eszter, Baranyi Marcell, Szigeti Krisztina, Hegedűs Luca, Bordás Fanni, Gábriel Zsófia, Petényi Gréta, Tóvári József, Hegedűs Balázs, Tímár József
Abstract excerpt
Pancreatic adenocarcinoma is one of the deadliest forms of cancer with no effective therapeutic options. A KRAS mutation can be found in up to 90% of all pancreatic tumors, making it a promising therapeutic target. The introduction of new KRAS inhibitors has been a milestone in the history of KRAS mutant tumors; however, therapeutic resistance limits their efficacy. Thus, new therapeutic options, including...
Topics
Join the communities discussing this publication.